Common and rare CARD14 gene variants affect the antitumour necrosis factor response among patients with psoriasis

P Coto-Segura1,2, D González-Fernández1, A Batalla1

  • 1Department of Dermatology, Hospital Universitario Central Asturias, Oviedo, Spain.

Insights

Specific CARD14 gene variants may influence patient response to anti-tumour necrosis factor (anti-TNF) therapies for psoriasis. The common p.Arg820Trp variant and rare missense variants were linked to better treatment outcomes.

Area of Science:

  • Genetics and immunology
  • Dermatology
  • Pharmacogenomics

Background:

  • The CARD14 gene is implicated in inflammatory pathways and psoriasis development.
  • CARD14 variants are associated with psoriasis risk.
  • This study investigates CARD14 variants' role in anti-TNF therapy response.

Purpose of the Study:

  • To determine if CARD14 gene variants correlate with positive responses to anti-tumour necrosis factor (anti-TNF) therapies in psoriasis patients.

Main Methods:

  • Next-generation sequencing of the CARD14 gene in 116 psoriasis patients.
  • Analysis of allele and genotype frequencies in responders versus non-responders.

Main Results:

  • A common CARD14 variant, rs11652075 CC (p.Arg820Trp), was significantly more frequent in responders (P = 0.01).
  • Rare CARD14 variants (p.Glu422Lys and p.Arg682Trp) were also observed more frequently in responders.

Conclusions:

  • The CARD14 p.Arg820Trp variant may significantly impact anti-TNF therapy effectiveness in psoriasis.
  • Rare CARD14 missense variants might also predict a better response to these therapies.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
67
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
732
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.3K